Catherine A Brady
Overview
Explore the profile of Catherine A Brady including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cundy N, Hare R, Tang T, Leach A, Jowitt T, Qureshi O, et al.
RSC Chem Biol
. 2022 Jan;
2(6):1651-1660.
PMID: 34977580
The metabolism of l-tryptophan to -formyl-l-kynurenine by indoleamine-2,3-dioxygenase 1 (IDO1) is thought to play a critical role in tumour-mediated immune suppression. Whilst there has been significant progress in elucidating the...
2.
Roberts A, Bentley L, Tang T, Stewart F, Pallini C, Juvvanapudi J, et al.
Sci Rep
. 2021 Feb;
11(1):4030.
PMID: 33597595
Blockade of PD-1/PD-L1 interactions is proving an exciting, durable therapeutic modality in a range of cancers whereby T cells are released from checkpoint inhibition to revive their inherent anti-tumour activity....
3.
Roberts A, Grafton G, Powell A, Brock K, Chen C, Xie D, et al.
J Pharmacol Exp Ther
. 2020 Feb;
373(1):122-134.
PMID: 32102919
The 5-hydroxytryptamine (5-HT) (serotonin) 5-HT receptor represents a clinical target for antagonists to deliver symptomatic relief to patients with diarrhea-predominant irritable bowel syndrome (IBS-d) or carcinoid syndrome. Unfortunately, this pharmacological...
4.
Ahmed S, Newman A, ODaly J, Duffy S, Grafton G, Brady C, et al.
Int Immunopharmacol
. 2016 Dec;
42:108-114.
PMID: 27912146
Inosine Acedoben Dimepranol (IAD), licensed for the treatment of cell-mediated immune deficiencies associated with viral infections, has been reported to impact a variety of immune parameters both in vitro and...
5.
Manning D, Guo C, Zhang Z, Ryan K, Naginskaya J, Choo S, et al.
Bioorg Med Chem Lett
. 2014 Apr;
24(11):2578-81.
PMID: 24755431
Serotonin type 3 (5-HT3) receptor partial agonists have been targeted as potential new drugs for the symptomatic relief of irritable bowel syndrome (IBS). Multiple diazepinone-based compounds have been discovered, which...
6.
Newman A, Batis N, Grafton G, Caputo F, Brady C, Lambert J, et al.
Br J Pharmacol
. 2013 Apr;
169(6):1228-38.
PMID: 23594147
Background And Purpose: The 5-HT₃ receptor is a ligand-gated ion channel that is modulated allosterically by various compounds including colchicine, alcohols and volatile anaesthetics. However the positive allosteric modulators (PAMs)...
7.
Manning D, Cioffi C, Usyatinsky A, Fitzpatrick K, Masih L, Guo C, et al.
Bioorg Med Chem Lett
. 2010 Dec;
21(1):58-61.
PMID: 21146988
Serotonin type 3 (5-HT(3)) receptor partial agonists are being targeted as potential new drugs for the treatment of irritable bowel syndrome (IBS). Two new chemical series bearing indazole and indole...
8.
Brady C, Dover T, Massoura A, Princivalle A, Hope A, Barnes N
Neuropharmacology
. 2007 Mar;
52(5):1284-90.
PMID: 17327132
The pentameric 5-HT(3) receptor complex is a ligand-gated ion channel that mediates fast synaptic transmission in the brain. Expression of two subunits (5-HT(3A) and 5-HT(3B) subunits) gives rise to at...
9.
Michel K, Zeller F, Langer R, Nekarda H, Kruger D, Dover T, et al.
Gastroenterology
. 2005 May;
128(5):1317-26.
PMID: 15887114
Background & Aims: Serotonin (5-hydroxytryptamine [5-HT]) is a key signaling molecule in the gut. Recently, the neural 5-HT3 receptor received a lot of attention as a possible target in functional...